Vascular biology: Cellular and molecular profiling

Seminars in Neurology

Volumn 26, Issue 1, 2006, Pages 65-74

  Baird, Alison E ^a   Wright, Violet L ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Endothelium; Gene expression; Lymphocyte; Peripheral blood

Indexed keywords

CD28 ANTIGEN; CD4 ANTIGEN;

BLOOD; BRAIN ATHEROSCLEROSIS; CAUSE OF DEATH; CD4+ T LYMPHOCYTE; ENDOTHELIUM; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; LYMPHOCYTE; PATHOGENESIS; PREDICTION; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEOMICS; REVIEW; RISK FACTOR; SECONDARY PREVENTION; STROKE; T LYMPHOCYTE;

EID: 33244484142     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-933310     Document Type: Review

References (60)

1. Corti R, Fuster V. New understanding, diagnosis, and prognosis of atherothrombosis and the role of imaging. Am J Cardiol 2003;91(suppl):17A-26A
2. Hirsch AT, Folsom AR. The continuum of risk. Vascular pathophysiology, function and structure. Circulation 2004;110:2774-2777
3. Hallenbeck JM, Dutka AJ. Background review and current concepts of reperfusion injury. Arch Neurol 1990;47:1245-1254
4. Libby P. Inflammation in atherosclerosis. Nature 2002;420: 868-874
5. DeGraba TJ. Immunogenetic susceptibility of atherosclerotic stroke. Implications on current and future treatment of vascular inflammation. Stroke 2004;35(suppl 1):2712-2719
6. Rost NS, Wolf PA, Kase CS, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 2001;32: 2575-2579
7. Curb JD, Abbott RD, Rodriguez BL, et al. C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation 2003;107:2016-2020
8. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565-575
9. Tanne D, Haim M, Boyko V, et al. Soluble intercellular adhesion molecule-1 and risk of future ischemic stroke: a nested case-control study from the Bezafibrate Infarction Prevention (BIP) study cohort. Stroke 2002;33:2182-2186
10. van Exel E, Gussekloo J, de Craen AJM, Bootsma-van der Wiel A, Frölich M, Westendorp RGJ. Inflammation and stroke: the Leiden 85-plus study. Stroke 2002;33:1135-1138
11. Davies PF. Molecular phenotypes of atherosclerosis. Fingering the perpetrators. Arterioscler Thromb Vasc Biol 2004;24: 1746-1747
12. Ridker PM, Cannon CP, Morrow D, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-28
13. DeGraba TJ, Siren A-L, Penix L, et al. Increased endothelial expression of intercellular adhesion molecule-1 (ICAM-1) in symptomatic vs asymptomatic carotid atherosclerotic plaque. Stroke 1998;29:1405-1410
14. Nadareishvili ZG, Ruetzler C, Szekely B, LaBiche R, DeGraba TJ. CD4-CD154 receptor ligand interaction in Chlamydia pneumoniae positive atherosclerotic plaque. Neurology 2001;56:A462
15. Kochanek PM, Hallenbeck JM. Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke 1992;23:1367-1379
16. Ernst E, Hammerschmidt DE, Bagge U, Matrai A, Dormandy JA. Leukocytes and the risk of ischemic diseases. JAMA 1987;257:2318-2324
17. Grau AJ, Boddy AW, Dukovic DA, et al. CAPRIE Investigators. Leukocyte count as an independent predictor of recurrent ischemic events. Stroke 2004;35:1147-1152
18. Chapman CM, Beilby JP, McQuillan BM, Thompson PL, Hung J. Monocyte count, but not C-reactive protein or interleukin-6, is an independent risk marker for subclinical carotid atherosclerosis: Stroke 2004;35:1619-1624
19. Garlichs CD, Kozina S, Fateh-Moghadam S, et al. Upregulation of CD40-CD40 ligand (CD154) in patients with acute cerebral ischemia. Stroke 2003;34:1412-1418
20. Chen W, Wahl SM. TGF-beta: the missing link in CD4(+)CD25(+) regulatory T cell-mediated immunosuppression. Cytokine Growth Factor Rev 2003;14:85-89
21. Becker KJ. Targeting the central nervous system inflammatory response in ischemic stroke. Curr Opin Neurol 2001;14:349-353
22. Alvord EC Jr, Hsu PC, Thron R. Leuokocyte sensitivity to brain fractions in neurological diseases. Arch Neurol 1974;30:296-299
23. Youngchaiyud U, Coates AS, Whittingham S, Mackay IR. Cellular immune response to myelin protein: absence 'in multiple sclerosis and presence in cerebrovascular accidents. Aust N Z J Med 1974;4:535-538
24. Wang WZ, Olsson T, Kostulas V, Hojeberg B, Ekre HP, Link H. Myelin antigen reactive T cells in cerebrovascular diseases. Clin Exp Immunol 1992;88:157-162
25. Namekawa T, Wagner UG, Goronzy JJ, Weyand CM. Functional subsets of CD4 T cells in rheumatoid synovitis. Arthritis Rheum 1998;41:2108-2116
26. Liuzzo G, Kopecky SL, Frye RL, et al. Perturbation of the T-cell repertoire in patients with unstable angina. Circulation 1999;100:2135-2139
27. Weyand CM, Gorozny JJ, Liuzzo G, et al. T-cell immunity in acute coronary and syndromes. Mayo Clin Proc 2001;76: 1011-1020
28. Edmead CE, Lamb JR, Hoyne GF. The T cell surface protein, CD28. Int J Biochem Cell Biol 1997;29:1053-1057
29. Nakajima T, Schulte S, Warrington KJ, et al. T-cell-mediated lysis of endothelial cells in acute coronary syndromes. Circulation 2002;105:570-575
30. Vallejo AN, Schirmer M, Weyand CM, Goronzy JJ. Clonality and longevity of CD4+CD28null T cells are associated with defects in apoptotic pathways. J Immunol 2000;165:6301-6307
31. - lymphocytes and stroke recurrence and death. Neurology 2004;63:1446-1451
32. Gerli R, Schillaci G, Giordano A, et al. CD4+CD28 - T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 2004;109:2744-2748
33. Ostrowski SR, Gerstoft J, Pedersen BK, Ullum H. A low level of CD4+CD28+ T cells is an independent predictor of high mortality in human immunodeficiency virus type 1-infected patients. J Infect Dis 2003;187:1726-1734
34. - lymphocytes following ischemic stroke. Stroke 2005;36:517 (Abstract)
35. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991;325:445-453
36. Toole JF, on behalf of the ACAS Executive Committee. ACAS recommendations for carotid endarterectomy. Lancet 1996;347:121
37. Combes V, Simon AC, Grau GE, et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 1999;104: 93-102
38. Berckmans RJ, Neiuwland R, Boing AN, Romijn FP, Hack CE, Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 2001;85:639-646
39. Simak J, Gelderman M, Yu H, Wright V, Alberts-Grill N, Baird AE. Elevated circulating endothelial microparticles in acute stroke patients: a correlation with brain lesion volume and clinical outcome. Blood 2004;104:3504 (Abstract)
40. Gretarsdottir S, Thorleifsson G, Reynisdottir ST, et al. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat Genet 2003;35:131-138
41. Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004;36:233-239
42. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995;270:467-470
43. Lockhart DJ, Dong H, Byrne MC, et al. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 1996;14;1675-1680
44. Virtanen C, Ishikawa Y, Honjoh D, et al. Integrated classification of lung tumors and cell lines by expression profiling. Proc Natl Acad Sci USA 2002;99:12357-12362
45. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511
46. Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000;406:536-540
47. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001;98:13790-13795
48. Van de Vijver MJ, He YD, van't Veer LJ, et al. A gene expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009
49. Jones MH, Virtanen C, Honjoh D, et al. Two prognostically significant subtypes of high-grade lung neuroendocrine tumors independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 2004;363:775-781
50. Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003;362: 362-369
51. Barrans JD, Allen PD, Stamatiou D, Dzau VJ, Liew CC. Global gene expression profiling of end-stage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray. Am J Pathol 2002;160:2035-2043
52. Moore DF, Li H, Jeffries N, et al. Using peripheral blood mononuclear cells to determine a gene expression profile of acute ischemic stroke: a pilot investigation. Circulation 2005;111:212-221
53. Jison ML, Munson PJ, Barb JJ, et al. Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic and inflammatory stress of sickle cell disease. Blood 2004;104:270-280
54. Seo D, Wang T, Dressman H, et al. Gene expression phenotypes of atherosclerosis. Arteriosder Thromb Vasc Biol 2004;24:1922-1927
55. Greenberg SA. DNA microarray gene expression analysis and its application to neurological disorders. Neurology 2001;57: 755-761
56. Napoli C, Lerman LO, Sica V, Lerman A, Tajana G, de Nigris F. Microarray analysis: a novel research tool for cardiovascular scientists and physicians. Heart 2003;89:597-604
57. Coffins FS, Green ED, Guttmacher AE, Guyer MS, on behalf of the US National Human Genome Research Institute. A vision for the future of genomics research. Nature 2003;422:835-847
58. Anderson L. Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J Physiol 2005;563: 23-60
59. Allard L, Lescuyer P, Burgess J, et al. ApoC-I and ApoC-III as potential plasmatic markers to distinguish between ischemic and hemorrhagic stroke. Proteomics 2004;4:2242-2251
60. Lynch JR, Blessing R, White WD, Grocott HP, Newman MF, Laskowitz DT. Novel diagnostic test for acute stroke. Stroke 2004;35:57-63